Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > Friday or 4pm NR is better

<< Previous

Bullboard Posts

Next >>

Comment by Momo25on Jan 21, 2022 9:57am

127 Views

Post# 34341799

RE:RE:Friday or 4pm NR is better

As always, same rethoric instaed of facts, such as something good behind the scenes but we don't know how good it is. All of that doesn't mean anything to the market. What market is expecting, is a clear and understandable communication from the management stating where the trial is heading and what are the next steps. Period. The rest is a kind of cerebral masturbation.

<< Previous

Bullboard Posts

Next >>

Near-term and long-term outlook for gold